EUK Fundamental Analysis - EUKEDOS SPA

Name: EUKEDOS SPA (EUK) Stock
Brand: EUKEDOS SPA
Rating: 0.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to EUK. EUK was compared to 27 industry peers in the Health Care Providers & Services industry. EUK has a medium profitability rating, but doesn't score so well on its financial health evaluation. EUK has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EUK has reported negative net income.

In the past year EUK had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: EUK reported negative net income in multiple years.

In the past 5 years EUK always reported a positive cash flow from operatings.

1.2 Ratios

With a Return On Assets value of -0.29%, EUK is not doing good in the industry: 74.07% of the companies in the same industry are doing better.

EUK has a worse Return On Equity (-1.76%) than 77.78% of its industry peers.

The Return On Invested Capital of EUK (2.53%) is worse than 70.37% of its industry peers.

EUK had an Average Return On Invested Capital over the past 3 years of 2.58%. This is below the industry average of 6.04%.

		Industry Rank	Sector Rank
ROA	-0.29%
ROE	-1.76%
ROIC	2.53%

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

1.3 Margins

With an excellent Operating Margin value of 10.03%, EUK belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.

In the last couple of years the Operating Margin of EUK has grown nicely.

EUK has a Gross Margin of 94.58%. This is amongst the best in the industry. EUK outperforms 96.30% of its industry peers.

EUK's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	10.03%
PM (TTM)	N/A
GM	94.59%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EUK is destroying value.

The number of shares outstanding for EUK remains at a similar level compared to 1 year ago.

EUK has about the same amout of shares outstanding than it did 5 years ago.

EUK has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.33, we must say that EUK is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of 0.33, EUK is not doing good in the industry: 85.19% of the companies in the same industry are doing better.

A Debt/Equity ratio of 3.11 is on the high side and indicates that EUK has dependencies on debt financing.

With a Debt to Equity ratio value of 3.11, EUK is not doing good in the industry: 74.07% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	3.11
Debt/FCF	N/A
Altman-Z	0.33

ROIC/WACC0.53

WACC4.78%

2.3 Liquidity

EUK has a Current Ratio of 0.38. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.

EUK's Current ratio of 0.38 is on the low side compared to the rest of the industry. EUK is outperformed by 85.19% of its industry peers.

A Quick Ratio of 0.38 indicates that EUK may have some problems paying its short term obligations.

The Quick ratio of EUK (0.38) is worse than 85.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.38
Quick Ratio	0.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EUK have decreased strongly by -260.63% in the last year.

EUK shows a small growth in Revenue. In the last year, the Revenue has grown by 4.81%.

The Revenue has been decreasing by -0.94% on average over the past years.

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EUK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

EUK's Enterprise Value to EBITDA ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	9.28

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EUK!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EUKEDOS SPA

BIT:EUK (10/23/2025, 7:00:00 PM)

0.765

-0.05 (-5.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners1.98%

Ins Owner ChangeN/A

Market Cap17.40M

Revenue(TTM)51.30M

Net Income(TTM)-524000

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.34
P/FCF	N/A
P/OCF	1.75
P/B	0.58
P/tB	1.8
EV/EBITDA	9.28

EPS(TTM)-0.05

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.58

FCFYN/A

OCF(TTM)0.44

OCFY57.12%

SpS2.22

BVpS1.31

TBVpS0.42

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.29%
ROE	-1.76%
ROCE	3.37%
ROIC	2.53%
ROICexc	2.6%
ROICexgc	3.01%
OM	10.03%
PM (TTM)	N/A
GM	94.59%
FCFM	N/A

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

ROICexc(3y)2.64%

ROICexc(5y)2.29%

ROICexgc(3y)3.08%

ROICexgc(5y)2.68%

ROCE(3y)3.43%

ROCE(5y)2.97%

ROICexgc growth 3Y-1.81%

ROICexgc growth 5Y0.32%

ROICexc growth 3Y-1.47%

ROICexc growth 5Y0.29%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

F-Score4

Asset Turnover0.28

Health

		Industry Rank	Sector Rank
Debt/Equity	3.11
Debt/FCF	N/A
Debt/EBITDA	7.67
Cap/Depr	327.21%
Cap/Sales	45.72%
Interest Coverage	250
Cash Conversion	82.01%
Profit Quality	N/A
Current Ratio	0.38
Quick Ratio	0.38
Altman-Z	0.33

F-Score4

WACC4.78%

ROIC/WACC0.53

Cap/Depr(3y)160.89%

Cap/Depr(5y)115.09%

Cap/Sales(3y)22.9%

Cap/Sales(5y)16.27%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-2.86%

EBIT growth 3Y3.47%

EBIT growth 5Y2.9%

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-466.09%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1.41%

OCF growth 3Y20.95%

OCF growth 5Y10.45%

EUKEDOS SPA / EUK.MI FAQ

Can you provide the ChartMill fundamental rating for EUKEDOS SPA?

ChartMill assigns a fundamental rating of 1 / 10 to EUK.MI.

What is the valuation status of EUKEDOS SPA (EUK.MI) stock?

ChartMill assigns a valuation rating of 0 / 10 to EUKEDOS SPA (EUK.MI). This can be considered as Overvalued.

What is the profitability of EUK stock?

EUKEDOS SPA (EUK.MI) has a profitability rating of 4 / 10.

Can you provide the financial health for EUK stock?

The financial health rating of EUKEDOS SPA (EUK.MI) is 1 / 10.

EUKEDOS SPA (EUK.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

EUKEDOS SPA / EUK.MI FAQ

Can you provide the ChartMill fundamental rating for EUKEDOS SPA?

What is the valuation status of EUKEDOS SPA (EUK.MI) stock?

What is the profitability of EUK stock?

Can you provide the financial health for EUK stock?